We are recruiting for the Bayer Arastep study for men with High Risk Biochemical recurrence (BCR). This trial is for men who have evidence of a prostate cancer lesion (s) by PSMA PET/CT scan with a rise in PSA blood levels, during or following prostate cancer treatment.